PVLA
NASDAQ HealthcarePalvella Therapeutics, Inc. - Common Stock
Biotechnology
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
�� 市场数据
| 价格 | $104.67 |
|---|---|
| 成交量 | 200,402 |
| 市值 | 1.50B |
| RSI（14日） | 30.9 |
| 200日均线 | $94.19 |
| 50日均线 | $121.33 |
| 52周最高 | $151.18 |
| 52周最低 | $20.20 |
| Forward P/E | -15.67 |
| Price / Book | 6.45 |
🎯 投资策略评分
PVLA 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🔪 Falling Knife (70/100) — 此策略 逆向投资（超卖 + 低于移动均线）.
评分最低的策略： 🎈 Over-Hyped (9/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 PVLA in your text
粘贴任何文章、记录或帖子 — 工具将提取 PVLA 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-06-02.